October 1985

Clomipramine Treatment of Childhood Obsessive-Compulsive DisorderA Double-blind Controlled Study

Author Affiliations

From the Child Psychiatry Branch, National Institute of Mental Health, Bethesda, Md (Drs Flament and Rapoport, Ms Berg, and Mr Sceery); the Clinical Psychopharmacology Section, Department of Psychiatry, Duke University Medical Center, Durham, NC (Dr Kilts); the Department of Clinical Pharmacology, Huddinge University Hospital, Huddinge, Sweden (Dr Mellström); and the Laboratory of Clinical Studies, National Institute on Alcohol Abuse and Alcoholism, Bethesda (Dr Linnoila).

Arch Gen Psychiatry. 1985;42(10):977-983. doi:10.1001/archpsyc.1985.01790330057007

• Nineteen children (mean [±SD] age, 14.5±2.3 years) with severe, primary obsessive-compulsive disorder completed a ten-week, double-blind, controlled trial of clomipramine hydrochloride (mean dosage, 141 mg/day) or placebo, each of which was administered for five weeks. Half of the subjects had not responded to previous treatment with other tricyclic antidepressants. There was a significant improvement in observed and self-reported obsessions and compulsions that was independent of the presence of depressive symptoms at baseline. Improvement in obsessive-compulsive symptoms did not correlate significantly with plasma concentrations of the drug or its metabolites. Clomipramine appears to be effective in the treatment of children with obsessive-compulsive disorder and the treatment seems to be independent of an antidepressant effect.